Novo Nordisk CEO defends lawsuit against Eli Lilly: ‘Competition has to be fair’
Novo Nordisk CEO defended the company’s decision to sue rival Eli Lilly over its weight-loss drug advertising. Source link
Tag: Markets
Jim Cramer says this former Covid market darling is finally investable again
Moderna’s expanding pipeline beyond infectious diseases is giving investors a new reason to own the stock after years of uncertainty following the Covid-19 pandemic, CNBC’s Jim Cramer said Wednesday. “For the first time in a long time, the company seems like it has something to get excited about,” the “Mad Money” host said, before advising…
Read More “Jim Cramer says this former Covid market darling is finally investable again” »
AstraZeneca CEO says AI is reshaping drug development — and helping boost the odds of success
AstraZeneca CEO Pascal Soriot said artificial intelligence is helping drugmakers develop medicines faster and make smarter decisions throughout the research process. “The value of AI in our industry is productivity improvement,” Soriot said on CNBC’s “Mad Money” on Friday. “In the way you design a new medicine, a new drug, you can actually do it…
AstraZeneca stock jumps after surprise trial win for lung disease drug where rivals have failed
AstraZeneca‘s stock rose over 3% after Britain’s most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment tozorakimab, reduced flare-ups of chronic obstructive pulmonary disease (COPD) in both former smokers and in the overall population versus placebo, the company said. “This marks a notable shift…
In this fast-paced bull market, we’re increasing our Club price targets on 4 stocks
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re…
Read More “In this fast-paced bull market, we’re increasing our Club price targets on 4 stocks” »